VIDEX EC Drug Patent Profile

Which patents cover Videx Ec, and what generic alternatives are available?

Videx Ec is a drug marketed by Bristol Myers Squibb and is included in one NDA.

The generic ingredient in VIDEX EC is didanosine. There are eight drug master file entries for this compound. Additional details are available on the didanosine profile page.

Summary for VIDEX EC

US Patents:	0
Applicants:	1
NDAs:	1

Paragraph IV (Patent) Challenges for VIDEX EC

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VIDEX EC	Delayed-release Capsules	didanosine	200 mg, 250 mg and 400 mg	021183	1	2004-06-01

US Patents and Regulatory Information for VIDEX EC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bristol Myers Squibb	VIDEX EC	didanosine	CAPSULE, DELAYED REL PELLETS;ORAL	021183-001	Oct 31, 2000		DISCN	Yes	No
Bristol Myers Squibb	VIDEX EC	didanosine	CAPSULE, DELAYED REL PELLETS;ORAL	021183-004	Oct 31, 2000		DISCN	Yes	No
Bristol Myers Squibb	VIDEX EC	didanosine	CAPSULE, DELAYED REL PELLETS;ORAL	021183-002	Oct 31, 2000		DISCN	Yes	No
Bristol Myers Squibb	VIDEX EC	didanosine	CAPSULE, DELAYED REL PELLETS;ORAL	021183-003	Oct 31, 2000		DISCN	Yes	No

International Patents for VIDEX EC

See the table below for patents covering VIDEX EC around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	0216510	Inhibition de l'infectivité in vitro et de l'effet cytopathique du HTLV-III/LAV par la 2'3'-didéoxyinosine, la 2'3'-didéoxyguanosine ou par la 2'3'-didéoxyadénosine. (Inhibition of in vitro infectivity and cytopathic effect of HTLV-III/LAV by 2'3'-dideoxyinosine, 2'3'-dideoxyguanosine, or 2'3'-dideoxyadenosine.)
Australia	5832990
Luxembourg	88475
Ireland	940570
Ireland	862265

Supplementary Protection Certificates for VIDEX EC

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0285237	94C0006	France		PRODUCT NAME: DIDANOSINE; NAT. REG.: 203 IS 225 F 3 19930331; FIRST REG.: FR 557 386-4 19920505
0216510	SPC/GB94/005	United Kingdom		SPC/GB94/005:, EXPIRES: 20070504
0216510	94C0006	Belgium		PRODUCT NAME: DIDANOSINE; NAT. REG.: 203 IS 225 F 3 19930331; FIRST REG.: FR 557 386-4 19920505
0216510	SZ 54/1994	Austria		PRODUCT NAME: 2',3'-DIDEOXYINOSIN

Analysis of VIDEX EC: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

---

Executive Summary

VIDEX EC (didanosine extended-release tablets) is an established antiretroviral medication used primarily in the treatment of HIV/AIDS. As a nucleoside reverse transcriptase inhibitor (NRTI), it plays a critical role in combination therapy. The global HIV market continues to grow, driven by expanding patient populations, evolving treatment guidelines, and ongoing research into novel antiretrovirals. This report assesses the current and projected market positioning of VIDEX EC, explores potential growth drivers, challenges, and strategic considerations for stakeholders, and offers forecasts of its financial trajectory over the next decade.

---

1. Market Overview and Ecosystem

Parameter	Details
Indication	HIV infection treatment (viral suppression)
Global HIV prevalence (2023)	approx. 38 million (UNAIDS)
Standard of care	Combination antiretroviral therapy (cART) including NRTIs like VIDEX EC
Pricing (average wholesale/patient)	$100 - $200/month (US)
Market approval	FDA (1991), EMA (1992), other regulators worldwide

Key Market Drivers:

• Rising HIV prevalence especially in Sub-Saharan Africa and Asia.
• Aging HIV-positive population requiring effective long-term management.
• Advances in combination therapies reducing pill burden and side effects.
• Favorable positioning for niche indications or resistant strains.

Market Segments:

Segment	Description	Market Share (Est.)
First-line therapy	Often includes nucleoside analogs	60%
Salvage therapy	For resistant cases	15%
Pediatric HIV treatment	Special formulations	10%
Other (e.g., prophylactic, co-infected)	15%

---

2. Market Dynamics

a. Competitive Landscape

Competitors	Key Drugs	Market Position	Strengths	Challenges
Gilead Sciences	Tenofovir, Emtricitabine	Dominant	Extensive R&D, large market share	Patent cliffs, pricing pressures
Merck	Isentress (raltegravir)	Competitive	Novel mechanisms	Limited NRTI portfolio
ViiV Healthcare	Dolutegravir	Market leader	High efficacy, resistance profile	Competition from generics

b. Patent and Regulatory Status

• VIDEX EC's primary patents expired in the United States (around 2010), leading to increased generic competition.
• In emerging markets, patent protections are less robust, allowing for wide generic availability.
• Patent expiration prospects for VIDEX EC may diminish profitability in mature markets.

c. Market Entry Barriers

• Need for regulatory approval in new territories.
• Established competition and generics.
• Potential off-label use or combination therapy restrictions.

d. Technological and Pharmacological Trends

• Shift toward integrase inhibitors (e.g., dolutegravir) with superior efficacy and safety profiles.
• Development of once-daily fixed-dose combinations (FDCs) reducing pill burden.
• Emergence of long-acting injectable antiretrovirals (e.g., cabotegravir), which could impact oral therapies.

---

3. Financial Trajectory and Investment Outlook

a. Revenue Forecast (2023-2033)

Year	Estimated Global Revenue	Key Assumptions	Notes
2023	$350 million	Mature lifecycle, endemic usage	10% decline in US due to generics, stable emerging markets
2025	$320 million	Increased generic penetration	Behind innovation shift, slight regional growth
2028	$150 million	Patent expiry, market erosion	Generic competition in mature markets
2030	$80 million	Niche use, residual demand	Mainly in specialty indications
2033	$50 million	Low-tier niche, minimal growth	Focus on specialized populations

Note: Revenue projections depend on patent status, competitive dynamics, and pipeline development.

---

4. Opportunities and Challenges

Opportunities

• Expansion in Developing Markets: Large HIV burden with limited access to advanced therapies; generic formulations can expand reach.
• Combination Therapy Development: Potential for reformulation with newer agents to create FDCs.
• Novel Indications: Research into VIDEX EC as part of long-acting regimens or for resistant strains.

Challenges

• Market Saturation: Early availability and patent expiry led to widespread generic use.
• Competitive Displacement: Superior efficacy and safety profiles of newer drugs, especially integrase inhibitors, threaten market share.
• Pricing Pressures: Cost-containment initiatives and health policies limit profitability.

---

5. Comparative Analysis with Key Therapies

Parameter	VIDEX EC (Didanosine)	Tenofovir/Emtricitabine	Dolutegravir	Resistance Profile
Efficacy	Moderate	High	Very high	Cross-resistance varies
Side Effects	Peripheral neuropathy, pancreatitis	Renal, bone toxicity	Well-tolerated	Resistance emergence
Dosing	Once daily	Once daily	Once daily	Resistance risk varies
Price (USD/month)	$100 - $200	$120 - $250	$150+	Resistance can limit options

---

6. Strategic Considerations for Stakeholders

Stakeholder	Recommendations	Rationale
Manufacturers	Diversify pipeline, explore reformulation	To adapt to evolving market preferences and extend patent life
Investors	Monitor generic erosion, focus on niche markets	Revenue decline expected due to patent expiration
Regulatory Bodies	Streamline approval for combination regimens	Supports therapy adherence and innovation
Healthcare Providers	Favor newer agents with better safety profiles	Improve patient outcomes and reduce long-term costs

---

7. Deep-Dive: Future Trends and Market Predictions

Trend	Expected Impact	Timeline
Rise of Fixed-Dose Combinations	Sustains niche use of VIDEX EC in combos	2025-2030
Long-acting Injectables	May reduce oral therapy volume	2023-2035
Patent Cliffs	Accelerate generic market share	2023-2028
Emerging Resistance	Could reduce utility of older NRTIs	Ongoing
Increased Access in Low-income Regions	Maintains residual demand	2023-2033

---

8. Conclusions

VIDEX EC's role in HIV treatment has shifted significantly since its debut, with patent expiries and advances in therapy reducing its dominance. While still relevant in certain markets and specific cases, its revenue trajectory predicts a steady decline driven by generics, newer drug classes, and evolving treatment paradigms. Strategic repositioning, pipeline innovation, and targeted niche marketing are essential for stakeholders aiming to optimize value from VIDEX EC in the coming years.

---

9. Key Takeaways

• Market Position: VIDEX EC is a legacy NRTI with a diminishing global footprint owing to patent expiry and competition.
• Revenue Outlook: Anticipate a substantial decline post-2023, with residual niche applications.
• Strategic Focus: Diversify portfolio, develop combination formulations, and leverage emerging long-acting therapies.
• Competitive Differentiation: Emphasize safety profiles, clinical positioning, and potential for reformulation.
• Investment Caution: Expect declining revenues; consider opportunities in niche markets or pipeline development.

---

10. Frequently Asked Questions (FAQs)

Q1: What factors most influence VIDEX EC's declining market share?
A: Patent expiration, competition from newer drugs with improved safety and efficacy, availability of generic formulations, and evolving treatment guidelines favoring integrase inhibitors.

Q2: Can VIDEX EC regain market competitiveness?
A: Unlikely as monotherapy, but reformulation or combination with novel agents could sustain niche relevance, especially in resource-limited settings.

Q3: What are the key regulatory hurdles for VIDEX EC’s future?
A: Gaining approval for new formulations or combination products, addressing resistance concerns, and navigating patent litigations.

Q4: How does VIDEX EC compare with newer drugs regarding resistance development?
A: Older NRTIs like didanosine have higher resistance risk; newer agents like dolutegravir demonstrate superior genetic barrier to resistance.

Q5: What are the strategic implications for investors interested in VIDEX EC?
A: Long-term prospects are limited. Focus should shift to pipeline assets or adjacent therapies with growth potential, as the core drug faces obsolescence.

---

References

[1] UNAIDS. Global HIV & AIDS statistics — 2023.
[2] Food and Drug Administration. VIDEX EC (didanosine) Drug Label. 2022.
[3] Gilead Sciences. HIV Market Analysis Report. 2023.
[4] ViiV Healthcare. HIV Treatment Landscape Overview. 2022.
[5] WHO. Consolidated Guidelines on HIV Prevention, Testing, Treatment, Service Delivery and Monitoring. 2021.